EGFR and cancer: Genomic alterations in anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) have been previously identified to be associated with a very high risk of VTE, whereas lower rates were reported for EGFR-mutated and ALK/ROS1/EGFR-wildtype cancers [13,14,15,16,17].